American Century Companies Inc. Boosts Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

American Century Companies Inc. boosted its position in Twist Bioscience Co. (NASDAQ:TWST) by 63.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 756,352 shares of the company’s stock after buying an additional 293,751 shares during the quarter. American Century Companies Inc.’s holdings in Twist Bioscience were worth $35,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Arizona State Retirement System increased its holdings in Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock worth $789,000 after acquiring an additional 219 shares during the last quarter. Van ECK Associates Corp boosted its position in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Twist Bioscience by 2.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after purchasing an additional 363 shares in the last quarter. US Bancorp DE lifted its stake in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares in the last quarter. Finally, D.A. Davidson & CO. lifted its stake in shares of Twist Bioscience by 3.5% during the 3rd quarter. D.A. Davidson & CO. now owns 19,618 shares of the company’s stock valued at $886,000 after buying an additional 664 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TWST. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Robert W. Baird raised their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,259 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the transaction, the senior vice president now directly owns 132,014 shares in the company, valued at $6,514,890.90. This trade represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Chess sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the director now owns 16,641 shares of the company’s stock, valued at approximately $832,050. The trade was a 23.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,799 shares of company stock worth $1,593,944 over the last 90 days. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Down 2.9 %

TWST stock opened at $40.36 on Friday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -11.94 and a beta of 2.15. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company’s 50 day moving average is $45.15 and its 200 day moving average is $45.33.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.